top of page
Relief belief
Eureka! We've found . . . out that we were awarded a grant from the National Institute on Drug Abuse (NIDA). In the coming year, using...
Screen saviors
High-throughput screening (HTS) has been a blessing and a curse. A blessing in codifying a straightforward approach to discovering drug...
Compound problem
Where to even begin? A mold flew in through the window and, presto, penicillin. Hey, then, why not screen all the compounds we have on...
Searching seizures
While most adverse phenotypes emerging in vivo late in drug development are unpredictable, progress has slowly but surely been made in...
Prediction looks to the future
It’s long been known that better early prediction of drug-like compound properties overcomes costly drug attrition later. But prediction...
Reading cancer's résumé
Thinking about battling cancer without understanding its tissue of origin would be like hiring someone without knowing about their...
Thymus up: the hidden powers of HCAC7
Some autoimmune diseases, like lupus, affect multiple tissues, but some, like inflammatory bowel disease, affect only specific types. A...
Purposeful repurposing
Drug repurposing is seen to be a major growth area in the drug development field because it trades the unsolved problem of attrition for...
Reducing safety-related drug attrition . . . the old-fashioned way
Everyone knows that off-targets are the bane of a drug developers existence, but surprisingly little has been done to address the...
Blog: Blog
bottom of page